Recent Updates
Recently added Catalysts
ATYR Negative Sentiment Score: 20/100

ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that aTyr Pharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Key Takeaway: A class action lawsuit has been initiated against aTyr Pharma, alleging that the company and certain officers made false and misleading statements about the efficacy of their drug Efzofitimod. The lawsuit focuses on claims that investors were misled regarding the drug's actual capabilities, particularly its ability to help patients reduce steroid use. This has led to investors purchasing shares at inflated prices based on these misleading representations. Affected investors are encouraged to join the lawsuit by the deadline of December 8, 2025.

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit has been filed against aTyr Pharma for alleged violations of federal securities laws.
  • The lawsuit alleges that aTyr made materially false and misleading statements regarding the drug Efzofitimod.
  • Investors claim that they purchased aTyr securities at artificially inflated prices due to these omissions and misrepresentations.
  • There are concerns about the drug's efficacy and its ability to enable patients to taper steroid usage.

Full Press Release Details

NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired aTyr securities between January 16, 2025 and September 12, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/ATYR.
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Defendants provided overwhelmingly positive statements to investors regarding the efficacy of Efzofitimod; (2) At the same time, Defendants disseminated false and misleading statements and/or concealed material adverse facts concerning the drug’s actual capability—particularly its ability to enable patients to completely taper their steroid usage; and (3) As a result of these omissions and misrepresentations, Plaintiff and other shareholders purchased aTyr’s securities at artificially inflated prices.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/ATYR. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in aTyr you have until December 8, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

Tags

Frequently Asked Questions

What is the class action lawsuit against aTyr Pharma about?

The lawsuit alleges aTyr made false statements about the drug Efzofitimod, misleading investors.

Who can join the aTyr class action lawsuit?

Anyone who purchased aTyr securities between January 16, 2025, and September 12, 2025.

What are the deadlines for participating in the lawsuit?

Investors must request to be lead plaintiff by December 8, 2025.

Are there any costs for joining the class action?

No, it is on a contingency fee basis; you pay only if the case is won.

How can I get more information about the lawsuit?

Visit bgandg.com/ATYR or contact Bronstein, Gewirtz & Grossman, LLC directly.

Last updated: Oct 17, 2025